A prospective, nationwide cohort study evaluating the safety and effectiveness of Infliximab Biosimilar in Patients with inflammatory bowel disease and Crohn's disease
Latest Information Update: 14 Feb 2020
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PROSIT
Most Recent Events
- 14 Feb 2020 New trial record